Clinical Practice

Every NCCN academic cancer center now reports a shortage of at least one anticancer medicine, led by ifosfamide (94%) and carboplatin (71%). Pharmacy directors say three years of policy have not moved the problem. #SyenzaNews #DrugShortages #Oncology #MarketAccess

NICE has opened consultation on draft guidance that does not recommend lenacapavir for HIV PrEP, finding the six-monthly injection is not value for money for the NHS in England. #SyenzaNews #HTA #HIV #PrEP #MarketAccess

An independent UK commission has published its recommendations for regulating AI in healthcare. The report calls for staged approvals and continuous real-world monitoring, alongside stronger enforcement powers for the MHRA. #SyenzaNews #AI #Healthcare #MarketAccess

Real-world UK data presented at ERS 2026 link semaglutide to fewer asthma attacks and COPD exacerbations. The indication stays metabolic, but the signal raises a real question for value and access teams. #SyenzaNews #MarketAccess #GLP1 #Respiratory

Camizestrant (Etcamah) gains accelerated FDA approval for ESR1-mutated advanced breast cancer, with median progression-free survival of 16 months versus 9.2 months in SERENA-6. #SyenzaNews #BreastCancer #FDA #Oncology

An Insilico Medicine phase 2a trial found six proteomic aging clocks all detected lower biological age in patients treated with rentosertib, an AI-designed drug for idiopathic pulmonary fibrosis. #SyenzaNews #Proteomics #AgingClocks #DrugDiscovery #IPF

Novo Nordisk has stopped the two remaining ziltivekimab heart failure trials after a futility review, leaving ARTEMIS as the last anti-inflammatory cardiovascular outcomes bet. #SyenzaNews #MarketAccess #Cardiology #HTA

Aspen Pharmacare has walked away from local lenacapavir manufacturing over the lack of guaranteed volumes, and is instead backing Merck's once-monthly oral PrEP pill, alimatravir. #SyenzaNews #HIV #PrEP #MarketAccess

Trump's Most Favored Nation drug pricing policy is already delaying new medicine launches in Europe. Brussels journalist Christoffer Frendesen unpacks the silence, the data, and why it may outlast the Trump presidency. #SyenzaNews #MarketAccess #DrugPricing

US Medicare is paying for obesity GLP-1s for the first time, and more than 500,000 seniors signed up in the first two months. Our latest breaks down the $245 price, the $50 copay, and what it means for Lilly and Novo Nordisk. #SyenzaNews #MarketAccess #GLP1 #Medicare

EMA's voluntary pre-submission pilot opens in September 2026. It adds earlier, more structured dialogue between applicants, rapporteurs and the Agency to curb premature filings. #SyenzaNews #MarketAccess #RegulatoryAffairs

CTS's Global Horizon panel brought four US operators to Montréal to explain why the US healthcare market rewards commercial readiness over good technology, and what founders can do about it. #SyenzaNews #MarketAccess #HealthTech